On July 29, Equifax rose 6.85% in regular trading, trading at $189.25/share, with turnover of $152 million. The stock continued its rebound from the post-Q2 earnings sell-off, supported by broad strength across the Research & Consulting Services sector.

Equifax reported Q2 adjusted EPS of $2.25, beating the consensus estimate of $2.20 by 2.27%, while revenue of $1.70 billion grew 11% year-over-year and topped expectations. Despite the beat, shares had previously declined to around $169 after the company issued Q3 EPS guidance of $2.15-$2.25, below the Street estimate of $2.26. However, the analyst consensus mean price target of $210.86 — with major banks including Morgan Stanley ($225), JPMorgan ($210), and UBS ($220) maintaining overweight/buy ratings — positioned the stock significantly below its perceived fair value, creating conditions for a sharp recovery.

Within the Research & Consulting Services sector, peer TransUnion surged 11.04% and Thomson Reuters gained 6.78%, indicating broad sector tailwinds. Equifax's AI-driven cost reduction target doubling to $150 million and the $825 million acquisition of Circulo de Credito further reinforce the company's long-term growth narrative.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)